(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Patent metadata

Field	Value
Publication number	US-11084810-B2
Application number	US-202016749412-A
Country	US
Kind code	B2
Filing date	Jan 22, 2020
Priority date	May 17, 2013
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

First claim

The invention claimed is:

1. A capsule containing

or a pharmaceutically acceptable salt thereof.

2. The capsule of claim 1 , wherein the capsule contains from 1 mg to 1000 mg of

or a pharmaceutically acceptable salt thereof.

3. The capsule of claim 1 , wherein the capsule contains from 25 mg to 500 mg of

or a pharmaceutically acceptable salt thereof.

4. The capsule of claim 1 , wherein the capsule contains

5. The capsule of claim 1 , wherein the capsule contains from 1 mg to 1000 mg of

6. The capsule of claim 1 , wherein the capsule contains from 25 mg to 500 mg of

7. A pill containing

or a pharmaceutically acceptable salt thereof.

8. The pill of claim 7 , wherein the pill contains from 1 mg to 1000 mg of

or a pharmaceutically acceptable salt thereof.

9. The pill of claim 7 , wherein the pill contains from 25 mg to 500 mg of

or a pharmaceutically acceptable salt thereof.

10. The pill of claim 7 , wherein the pill contains

11. The pill of claim 7 , wherein the pill contains from 1 mg to 1000 mg of

12. The pill of claim 7 , wherein the pill contains from 25 mg to 500 mg of

13. A tablet containing

or a pharmaceutically acceptable salt thereof.

14. The tablet of claim 13 , wherein the tablet contains from 1 mg to 1000 mg of

or a pharmaceutically acceptable salt thereof.

15. The tablet of claim 13 , wherein the tablet contains from 25 mg to 500 mg of

or a pharmaceutically acceptable salt thereof.

16. The tablet of claim 13 , wherein the tablet contains

17. The tablet of claim 13 , wherein the tablet contains from 1 mg to 1000 mg of

18. The tablet of claim 13 , wherein the tablet contains from 25 mg to 500 mg of

Assignees

• Centrexion Therapeutics Corp

Inventors

• Riether Doris
• Binder Florian Paul Christian
• Doods Henri
• Mueller Stephan Georg
• Nicholson Janet Rachel
• Sauer Achim

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D261/04

  having one double bond between ring members or between a ring member and a non-ring member · CPC title

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• C07D413/02

  containing two hetero rings · CPC title